

Article

MicroRNA Signatures of Prostate Cancer Spheroids in Microfluidic Culture Under Hormone-Deprivation Conditions

Kamaldeep Saini ¹, Theresa Kordaß ² , Zita Zena ¹, Martin Burchardt ¹, Cindy Roennau ^{1,†} and Pedro Caetano Pinto ^{1,*,†} 

¹ Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany

² Department of Visceral, Thoracic and Vascular Surgery, University Medicine Greifswald, 17475 Greifswald, Germany

* Correspondence: pedro.pinto@uni-greifswald.de

† These authors contributed equally to this work.

Abstract

Background: Prostate cancer (PCa) is prevalent in men over 65 and requires effective clinical management. Standard PCa therapies often offer positive outcomes; however, its castration-resistant form (CRPC) is aggressive and associated with poor prognosis. The objective of this study is to characterize the microRNA profiles associated with the PCa to CRPC transition using a microfluidic PCa model. **Methods:** LNCaP-derived hormone-sensitive PCa spheroids were cultured for 30 days under recirculating flow conditions mimicking hormone deprivation. Total RNA was isolated from the spheroids and perfusate at Day 5 and Day 30. Exosomal microRNAs were profiled by miRNA-seq. Differentially expressed miRNAs were used for target prediction across multiple databases, and gene set enrichment analysis (GSEA) was performed to identify pathways affected during prolonged hormone deprivation. **Results:** Sustained hormone deprivation induced a shift in microRNA expression. Tumor-suppressive miRNAs were broadly reduced. To evaluate functional consequences, predicted targets were compiled for all regulated miRNAs. For the 33 intracellular miRNAs downregulated on Day 30, 430 genes were predicted as targets for at least 16 of these miRNAs, revealing strong convergence on shared regulatory pathways. Thirty-five genes overlapped with predicted targets of the single upregulated miRNA and were removed, yielding a refined set of 395 unique genes used for GSEA. Overall, the neuronal differentiation pathways observed reflect early features of a neuroendocrine-like phenotype. **Conclusions:** This microfluidic PCa model captures early molecular events associated with progression toward CRPC. It provides a controlled system for studying disease evolution and supports the development of more precise therapeutic and diagnostic strategies.

Keywords: microRNA; prostate cancer; 3D cell culture; microfluidic cell culture; cancer progression



Academic Editor: Sudip K. Das

Received: 25 December 2025

Revised: 4 February 2026

Accepted: 6 February 2026

Published: 11 February 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the [Creative Commons Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction

Prostate cancer (PCa) remains one of the most common malignancies among men worldwide [1]. Disease progression is characterized by distinct pathophysiological transitions, from benign prostatic hyperplasia (BPH) to hormone-sensitive prostate cancer (HSPC) and ultimately to castration-resistant prostate cancer (CRPC), with profound changes in underlying cellular mechanisms [2,3]. Among the molecular regulators implicated in PCa

survival and proliferation, microRNAs (miRNAs) have emerged as key pathway regulators involved in gene expression [4], intercellular communication [5], cell proliferation and survival, epithelial–mesenchymal transition (EMT) [6], angiogenesis and immunogenicity [7]. PCa cells are prolific in miRNAs secretion, and several studies have identified individual miRNA associated with disease stage, aggressiveness, and therapy resistance. Considering that miRNAs can be detected in blood or urine, they have been long considered as promising biomarkers for disease diagnosis, prognosis, and therapeutic monitoring, using minimally invasive procedures [8].

The heterogeneity of miR expression across cancers and other pathologies presents a significant challenge to their clinical translation. Non-specific or overlapping expression patterns increase the risk of false positives and complicate the interpretation of miR-based assays [9]. Despite these challenges, a catalog of over 2000 identified human miRNAs, together with advances in isolation and analysis, has enabled the comprehensive characterization of cancer-associated miRNA increasingly feasible [10]. In PCa and other malignancies, miR secretion serves multiple biological functions [11]. Circulating miRNA can promote metastasis by targeting and disrupting tight junctions in vascular endothelium, facilitating tumor cell extravasation. They can modulate the tumor microenvironment by reprogramming surrounding stromal cells, such as cancer-associated fibroblasts (CAFs), to adopt tumor-supportive phenotypes [12]. Secreted miRNAs also enable immune evasion, suppressing cytotoxic responses or reprogramming T cells to adopt immunosuppressive activity and can reprogram the metabolism of host tissue [13,14]. In PCa, miRs have been associated with cell invasion, neuroendocrine trans-differentiation and castration-resistance progression [15,16]. Extracellular miRNAs can be found encapsulated within exosomes, which protect them from degradation in the extracellular space and mediate delivery to target cells [17]. This packaging confers multiple advantages, protects from enzymatic breakdown, mediates efficient intercellular communication and biocompatibility [18]. Exosomal membranes shield miR from immune detection and facilitate their extravasation through vessels and capillaries, mediating metastatic dissemination [19].

MiRNA signatures are defined as combinations of specific miRNAs that collectively indicate a disease state and are emerging as valuable diagnostic and prognostic tools. These signatures function as molecular fingerprints, capturing the pattern of altered miRNA expression characteristic of specific pathological processes [20,21]. Their prognostic potential is exemplified in a recent study using stool-based miRNA profiles for the early detection of colorectal cancer. A panel comprising *miR-21-5p* and *miR-199a-5p*, combined with patient age, achieved an 88% sensitivity for colorectal cancer detection. An expanded panel including *miR-451a* improved discrimination of high-grade dysplasia to 91% sensitivity. When integrated with fecal occult blood testing, these panels achieved 96% sensitivity for detecting high-grade lesions [22]. This approach underscores the diagnostic power of miR profiling relative to single-miRNA analysis. Identifying complex miR expression profiles in PCa rather than individual miRNAs can potentially characterize disease stage and predict the transition from hormone-sensitive to hormone-insensitive (castration-resistant) states [23,24]. Despite significant advances in the characterization of PCa-associated miRNAs, the mechanistic relationships behind their regulation and function remain elusive.

We previously developed a micro-physiology PCa model where cells are cultured under dynamic conditions, mimicking a microenvironment with active fluid circulation. In our system, PCa cells developed a robust epithelial phenotype and displayed prolific miRNA secretion [25]. In the present study, we introduce a new iteration of our microfluidic PCa model in which LNCaP spheroids are cultured for 30 days under androgen-depleted conditions. In this study, we aim to capture early phenotypic changes associated with the transition from hormone-sensitive to androgen-insensitive prostate cancer, in order to inves-

tigate microRNA signatures linked to the onset of castration resistance in a physiologically relevant and dynamic culture environment.

2. Materials and Methods

2.1. Cell and Microfluidic Culture

For maintenance and expansion, LNCaP cells (American Type Culture Collection, Manassas, VA, USA) were cultured under standard conditions using RPMI-1640 medium supplemented with sodium pyruvate, 10% (*v/v*) fetal calf serum (FCS), and 5% (*v/v*) penicillin–streptomycin (10,000 U/mL). To generate LNCaP spheroids, cells were harvested, resuspended as a single-cell suspension, and seeded at a density of 10,000 cells per well into individual wells of a Biofloat™ plate, allowing for uniform spheroid formation under non-adherent conditions. Spheroids were maintained in low-adhesion plates for three days before further processing. The hydrogel used for spheroid embedding consisted of 4% (*w/v*) agar mixed with rat tail collagen I (3 mg/mL) and culture medium at a ratio of 100 µL agar, 25 µL collagen, and 75 µL medium, resulting in a final mixture of 200 µL containing 2% agar and 1.1 mg/mL collagen. Eight LNCaP spheroids were collected into a 1.5 mL tube and gently mixed with the hydrogel solution, following the procedure described by Padmyastuti et al. [25]. The hydrogels were allowed to polymerize at 37 °C for 1 h, after which they were removed from the tubes and transferred to 24-well plates (one gel per well) containing 1 mL of standard culture medium.

For microfluidic culture, the Humimic Chip 2 24-well platform (TissUse GmbH, Berlin, Germany) was used. Each experimental condition included three biological replicates, each consisting of three hydrogels (containing a total of 24 spheroids) placed within the 24-well-sized compartment of the chip, with 1 mL of culture media. In this configuration, the adjacent 96-well-sized compartment of the chip was used for medium exchange and sample collection, with a volume of 0.5 mL. The hydrogels were perfused for 30 days under recirculating flow at a frequency of 25 Hz. The overall culture layout and experimental configuration are illustrated in Figure 1. To simulate androgen deprivation, charcoal-stripped FCS (csFCS) was used. For static reference cultures, hydrogels were maintained in conventional 24-well plates, with three hydrogels per well, under identical conditions (Table 1).

Table 1. Serum content in dynamic cell culture.

Condition	Serum (<i>v/v</i>)	Perfusion Period
Complete media (standard culture)	10% FCS	5 days
50% hormone depleted	5% FCS 5% csFCS	10 days
100% hormone depleted	10% csFCS	15 days

2.2. Cell Viability and PSA Secretion

To evaluate cell viability during the androgen-deprivation culture period, lactate dehydrogenase (LDH) release, caspase-3/7 activity, and metabolic activity were assessed. The Promega assay kits used for these analyses are listed in Appendix A, Table A1. For each assay, 25 µL of perfusate (effluent) was collected from the microfluidic circuit and processed according to the manufacturer’s specifications. Prostate-specific antigen (PSA) secretion was quantified using the DuoSet ELISA system (R&D Systems) following the protocol previously reported for PCa microfluidic culture [25].




Figure 1. Microfluidic culture setup and experimental conditions. (A–C) Hydrogels containing LNCaP spheroids used for dynamic and static cultures. (D) Standard static culture configuration prior to transfer into the microfluidic chip. (E) Humimic Chip 2 microfluidic system (TissUse GmbH, Berlin, Germany). (F) Microfluidic circuit layout showing three hydrogels positioned within the culture compartment. (G) Experimental timeline: perfusate samples were collected every 5 days for analysis. Culture media was replaced on Day 5, Day 15 and Day 30 with reduced androgen content. Hydrogels were collected for analysis at Day 5 and Day 30.

2.3. Morphological Characterization

Morphological characterization of LNCaP spheroids was performed using immunofluorescent markers associated with prostate cancer phenotype, polarity, adhesion, and cellular activity. These markers provide insight into the maintenance of epithelial organization and differentiation status under androgen-deprivation conditions. Spheroids cultured under static androgen-deprivation conditions were fixed with 4% paraformaldehyde (PFA) and permeabilized with 0.1% Triton X-100 (TXT) in Phosphate Saline buffer (PBS) overnight at 4 °C. Staining buffer consisted of 0.1%TXT in PBS with 2% bovine serum albumin (*w/v*), as a blocking agent. Washing buffer consisted of 0.1%TXT in PBS. Immunofluorescent staining was carried out according to the conditions listed in Table A2. All markers were

co-stained with Phalloidin-488 (f-actin) and Hoechst33342 (nuclei). All primary antibodies were incubated overnight at 4 °C and secondary antibodies the following day for 3 h at room temperature.

2.4. MicroRNA Isolation and Sequencing

For microRNA analysis, perfusate and hydrogel samples were collected from both 3D static and microfluidic cultures. Three hydrogels were combined to form a single sample, which was lysed in 750 µL TRIzol per 250 µL sample volume with 2% Triton X-100. Lysates were homogenized by repeated resuspension through a 20G needle and incubated at room temperature for 20 min. One volume of 100% ethanol was added to the lysate mixture, and total RNA, including microRNAs, was isolated using the Qiagen miRNeasy Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's specifications [25]. Exosomal small RNA sequencing (sRNA-seq) was performed by Novogene Europe (Munich, Germany), which included library construction with adapter ligation, reverse transcription, amplification, and size selection, followed by single-end 50 bp high-throughput sequencing in the Illumina NovaSeq 6000 high-throughput next-generation sequencing platform. Sequencing reads underwent quality control, mapping to the reference genome, and alignment for quantification of known microRNAs.

2.5. MicroRNA Expression Analysis

Pre-normalized transcript per million (TPM) expression data [26,27] for intracellular and extracellular (liquid phase) microRNAs were analyzed in R (v4.4.3). After import of the TPM matrices, non-numeric entries were converted to missing values and set to zero to ensure consistent data structure. TPM-normalized miRNA expression data from circulating samples (circulating miRNAs) collected at Day 5 (control, $n = 3$) and Day 30 ($n = 2$) were compared. Differential expression was assessed using two-sided t -tests for each miRNA (10.2202/1544-6115.1027), and miRNAs with $p < 0.05$ were considered differentially expressed. TPM-normalized intracellular miRNA expression profiles from Day 5 and Day 30 samples (each $n = 2$) were compared using two-sided t -tests for each miRNA. miRNAs with $p < 0.05$ were considered differentially expressed. Fold changes (FCs) were calculated as the ratio of mean expression from Day 30 to Day 5. miRNAs with $FC > 1$ were classified as upregulated at Day 30, and those with $FC < 1$ as downregulated. To support the sequencing analyses, the expression of the top deregulated miRNAs was examined in The Cancer Genome Atlas Prostate Adenocarcinoma (TCGA-PRAD) miRNA-Seq dataset: <https://portal.gdc.cancer.gov/projects/TCGA-PRAD> (accessed on 29 January 2026), with expression levels evaluated relative to the reference miRNA miR-16 [28].

2.6. Target Prediction Analysis

For the differentially expressed miRNAs, target gene prediction was performed using multiple established databases to ensure robust coverage of both conserved and non-conserved interactions [26]. The following resources were included: MicroCosm [29], microRNA.org (conserved and non-conserved targets) [30], miRDB v5 [31], miRecords [32], PicTar [33], PITA (including PITA_all) [34], and TargetScan [35]. Only genes predicted by at least two of these databases were retained for subsequent downstream analyses. Pathway enrichment analysis was performed using the predicted target gene lists derived from miRNAs upregulated or downregulated at Day 30. To identify pathways potentially activated at Day 30, enrichment was calculated for genes targeted by miRNAs that were downregulated at Day 30, as these targets are expected to be transcriptionally upregulated. Before analysis, genes that also appeared in the target list of upregulated miRNAs were excluded to avoid confounding effects. Only miRNA–target interactions supported by at least two independent databases were considered. To validate the expression of key

target genes identified in our study, miRNA expression and corresponding mRNA target expression were analyzed in the TCGA-PRAD dataset, with analyses restricted to experimentally validated targets of the three core miRNAs as defined by miRTarBase analysis described in Table 2. Progression-free survival (PFS) analysis was performed using the Gene Expression Profiling Interactive Analysis (GEPIA3) web-based platform to evaluate associations between mRNA expression levels and clinical outcome in the TCGA-PRAD dataset. The analyses were restricted to predicted and experimentally validated miRNA target genes identified and listed in Table 2. A summary of the TCGA-PRAD dataset analysis is described in Appendix C.

Table 2. List of genes within the regulatory hubs of the three most highly connected miRNAs.

miRNA	Genes
mir-186	PKNOX1, FARP1, MAP4, ZNF592, SPIN1, MON2, MAPK1, AKAP5, THSD4, CAMTA1, KPNA1, MAPK1IP1L, PHC3, PHF12, EPB41L4B, PTPN11, KPNA3, SHANK2, GNB4, EPHB1, SLC44A1, FAM168B, BCAT1, CDK14, LMBR1, RPS6KA3, ATXN7, GDF6, GATAD2B, RAB21, BNC2, FOXJ3, NAA15, LAMP2, SLC26A7, MAP3K2, PLS3, RNF2, SLC30A7, PLEKHA2
mir-9	TPM3, RANBP17, VANGL1, ELAVL1, MAP3K1, TRIM2, PCYT1B, OTUD3, MAP1B, FNIP2, RNF144A, PYGO2, KCTD10, PCGF5, ASXL1, VGLL4, ADAMTS9, FBXW2, HMGA2, RNF150, CPEB4, PHF20L1, FZD5, KLHL18, GREB1, AP4E1
mir-139	PDE4DIP, ATP7A, USP6NL, ZNF470, PHF6, TET2, KBTBD8, USP47, FAT3, PRKAR2A, ZEB2, MEX3A, WDR26, ZNF507, ELAVL2, DNAJC5, PPP3CB, ABI2
mir-186 and mir-9	ANO6, YPEL2, SYT10, SNX30, TMTC1, SIX4, CNOT6L, FBN1
mir-139 and mir-186	PDE4D, DNMT3, MEX3B, RUFY3, KIF3A, MGAT4A
mir-139 and mir-9	FOXP2, RFX7, GABBR2, NRP1
mir-139 and mir-186 and mir-9	ZBTB34

3. Results

3.1. PCa Spheroids Exhibit a Differentiated Epithelial Morphology

Morphological analysis using immunofluorescence staining of epithelial markers revealed a high degree of polarization and epithelial organization in LNCaP spheroids. Localization of F-actin almost exclusively to the cell boundaries (Figure 2A) supports this observation. EGFR was primarily localized to the periphery of the spheroids (Figure 2(B1,B2)), and cells displayed pronounced expression of ZO-1 (Figure 2(C1,C2)), tubulin (Figure 2D), and E-cadherin (Figure 2E) along their cellular boundaries. Brightfield images already suggested the presence of two distinct structural regions within the spheroids—an outer and an inner area. The spheroids displayed an oblique morphology, and the inner region did not form a compact core, as it was not fully enclosed by the outer layer but remained partially exposed to the external environment. The outer region is estimated to display a thickness between 100 and 150 µm, representing about 60–70% of the spheroid area. F-actin organization clearly delineates these two regions (Figure 2G), while ZO-1 and E-cadherin expression appeared more structured and continuous in the outer region, forming a distinct epithelial boundary most evident in the E-cadherin staining. Fibronectin

expression (Figure 2H) was predominantly observed in the outer region, indicating that cell–cell and cell–matrix adhesion in the inner region is comparatively weaker. Live/dead staining (Figure 2I) demonstrated that both regions contained viable cells, with no significant evidence of cell death in the inner compartment.




Figure 2. LNCaP spheroid morphology. (A) PCa spheroid (10x) with phalloidin-488 (f-actin) staining highlighting cell boundaries. (B1,B2) EGFR predominantly localized in the periphery of the spheroids. (C1,C2) ZO1 evident in the cell boundaries, highlighting their epithelial morphology. The staining displays a more dotted pattern in the core of the spheroid. (D1,D2) Tubulin expressed abundantly in the spheroids, delimiting cells, reiterating their epithelial morphology. (E1,E2) E-cadherin localized along a defined transition region between the spheroid periphery and core. (F) Bright field image of the PCa spheroids, where the boundary region is also evident as a high-contrast area. (G) F-actin staining detailing marked difference in morphology between the periphery and the spheroid core. (H) Fibronectin predominantly expressed in the spheroid peripheral area. (I) Live-dead stain where no differences in viability are evident between spheroid periphery and core.

3.2. Spheroid Viability Is Maintained Under Prolonged Microfluidic and Static Conditions

LNCaP spheroids maintained their viability under both microfluidic and static culture conditions over the 30-day experimental period, as indicated by stable LDH leakage throughout (Figure 3A). Caspase-3/7 activity gradually declined over time in both culture systems, with overall extracellular caspase activity remaining at baseline levels, suggesting no significant induction of apoptosis (Figure 3B). Assessment of dehydrogenase activity

using the PrestoBlue assay further confirmed that viability was preserved in static cultures, while microfluidic cultures displayed a marked increase in metabolic activity over time (Figure 3C). Additionally, PSA secretion was elevated in microfluidic cultures relative to static conditions, indicating maintained functional activity (Figure 3D). Collectively, these results demonstrate that the experimental culture conditions employed do not compromise LNCaP spheroid viability or functional integrity.




Figure 3. LNCaP spheroid viability. (A) LDH release shows that over a 30-day culture period, either under static or microfluidic conditions, spheroid viability remains constant. (B) Caspase activity is reduced in both static and microfluidic conditions, indicating that minimal cellular death activity occurs during the culture period. (C) The Presto-blue viability assays show an increase of about 2-fold in microfluidic conditions, while constant in static conditions. (D) Under microfluidic conditions, prostate specific antigen (PSA) secretion is stable, and elevated relative to static culture.

3.3. Hormone-Deprivation Conditions Alter MicroRNAs Expression Profile

To assess intracellular miRNA expression dynamics under hormone-deprivation conditions, TPM-normalized miRNA profiles from Day 5 and Day 30 samples were compared. One miRNA, *hsa-miR-125b-5p*, was found to be upregulated on Day 30 ($p < 0.05$). In contrast, 33 miRNAs and one novel miRNA (novel_262) were downregulated at Day 30 compared to Day 5 (Figure 4A).

These results indicate a predominant downregulation of intracellular miRNAs after prolonged hormone deprivation, suggesting a reduction in post-transcriptional regulatory activity at later stages of adaptation. For the extracellular (liquid phase) samples, TPM-normalized miRNA expression levels from Day 5 and Day 30 were compared. In total, the following eight miRNAs were significantly increased at Day 30 ($p < 0.05$): *hsa-miR-1323*, *hsa-miR-181a-2-3p*, *hsa-miR-192-5p*, *hsa-miR-205-5p*, *hsa-miR-302b-3p*, *hsa-miR-372-5p*, *hsa-miR-516a-5p*, and *hsa-miR-516b-5p* (Figure 4B). No overlap was observed between the significantly deregulated extracellular and intracellular miRNAs. However, several of the extracellularly increased miRNAs showed a similar trend toward higher expression intracellularly, although not reaching statistical significance. The expression of the top

downregulated miRNAs in our experimental (*miR-139*, *miR-186*, and *miR-9*) was also found to be significantly lower, compared with the reference miRNA, in the TCGA-PRAD database cohort. Conversely, the upregulated miRNA *miR-125b* showed significantly higher expression relative to the same reference miRNA.




Figure 4. Differential expression of intracellular and extracellular miRNAs. (A) Volcano plot showing intracellular miRNA expression changes between Day 30 and Day 5. Blue dots indicate miRNAs with lower expression at Day 30, and red dots represent miRNAs with higher expression at Day 30. (B) Volcano plot of extracellular (circulating) miRNAs comparing Day 30 vs. Day 5.

3.4. Deregulated microRNAs Profiles Are Associated with PCa Cancer Progression

To investigate the functional impact of the observed miRNA expression changes, we performed a comprehensive target prediction and pathway enrichment analysis for the intracellular miRNAs regulated at Day 30. For each differentially expressed miRNA, predicted target genes were retrieved from multiple databases, with the supporting sources documented for every interaction. Target lists were generated separately for miRNAs upregulated and downregulated on Day 30, and additional filtered gene sets were created based on increasing evidence thresholds (no cutoff, ≥ 2 databases, and ≥ 3 databases). We focused the pathway analysis on the predicted targets of the 33 intracellularly downregulated miRNAs on Day 30. Across these 33 miRNAs, 430 genes were predicted as targets for at least 16 of the 33 downregulated miRNAs, indicating substantial convergence on shared regulatory nodes. Of these, 35 genes overlapped with the predicted targets of the single upregulated miRNA (*hsa-miR-125b-5p*). To isolate pathways specifically influenced by the downregulated miRNAs, these 35 shared genes were removed, resulting in a final set of 395 unique target genes. This gene set was used as input for gene set enrichment analysis (GSEA). Experimentally validated targets for the three core miRNAs were identified using miRTarBase (Figure 5A,B). Among predicted targets, experimental validation was available for 4 of 39 targets for *miR-9-5p*, 10 of 55 targets for *miR-186-5p*, and 17 of 29 targets for *miR-139-5p* (Figure 6A,B). Correlation analysis between miRNA and target mRNA expression in PRAD samples revealed multiple significant negative correlations, consistent with functional miRNA–target regulation (Figure 6C). This effect was most pronounced for *miR-186-5p*, for which the majority of experimentally validated targets also exhibited significant negative correlations. Across all predicted targets listed in Table 2, negative correlations were observed for a substantial proportion of targets for each miRNA. Notably, *miR-139-5p* also showed strong positive correlations with several targets, including experimentally

validated genes such as PDE4D, PPP3CB, ZEB2, FOXP2, DNMT3, and FAT3, suggesting the presence of context-dependent regulatory mechanisms or feedback regulation (Appendix C, Table A3).




Figure 5. Pathway analysis of predicted target genes de-repressed at Day 30 due to miRNA downregulation. **(A)** Reactome/biological pathway enrichment performed on the 395 unique genes predicted to be upregulated (de-repressed) at Day 30 as a consequence of intracellular miRNAs being significantly downregulated. This analysis highlights specific signaling and cellular processes enriched among these predicted target genes. **(B)** Hallmark gene set enrichment (MSigDB) using the same set of de-repressed target genes. Hallmark gene sets capture broader, non-redundant biological programs and transcriptional states, complementing the more detailed pathway-level information in Panel **(A)**.

Pathway enrichment revealed that the predicted derepressed target genes clustered in distinct biological processes and signaling pathways, suggesting that coordinated downregulation of miRNAs at Day 30 may contribute to specific transcriptional reprogramming events during adaptation to hormone deprivation. The identification of pathways associated with vesicle-mediated transport and membrane trafficking is expected, given that our profiling focused on exosomal microRNAs, which are selectively packaged into exosomes. Interestingly, additional pathways related to chemical synapses, neurotransmitter signaling, and axon guidance suggest the emergence of neuronal differentiation features, highlighting a potential link between exosomal signaling and neuroendocrine-like phenotypes. Several predicted and experimentally validated target genes listed in Table 2 showed significant associations with progression-free survival (PFS). Specifically, lower expression of NRP1, GATAD2B, RUFY3, KIF3A, and ZBTB34 was associated with longer PFS. As these genes are predicted targets of the downregulated miRNAs identified in our dataset, these associations are consistent with a model in which increased miRNA expression is linked to improved clinical outcome through suppression of specific downstream target genes.




Figure 6. MicroRNA-gene interaction map. (A). Circos plot showing predicted interactions ($DB \geq 3$) between 33 miRNAs downregulated on Day 30 and their target genes. The network comprises 326 interactions linking 20 miRNAs to 173 genes. (B) Several genes (e.g., MAPK1, RPS6KA3, and NRP1) form major regulatory hubs. Among the miRNAs, miR-186-5p shows the highest connectivity (55 interactions), followed by miR-9-5p (39) and miR-139-5p (29). (C) Expression of selected miRNAs in the TCGA-PRAD cohort. The miRNAs miR-139, miR-186, and miR-9, which were downregulated in the experimental system, showed lower expression relative to the reference miRNA in the TCGA-PRAD dataset. In contrast, the upregulated miRNA miR-125b exhibited higher expression compared with the same reference miRNA. Statistical analyses were performed using one-way ANOVA followed by Dunnett's multiple-comparison test (**** $p < 0.01$).

4. Discussion

Available in vitro tools to study prostate cancer are restricted to a handful of cell lines derived from metastatic lesions. Because prostate tissue is less terminally differentiated than other organs of the urogenital tract, prostate cells tend to de-differentiate once isolated, drifting away from their native phenotype [36]. Among the most well characterized and widely used, Pca lines are LNCaP cells which were selected for our study. LNCaP cells are hormone-sensitive, PSA-secreting, androgen-receptor-positive, with a plastic phenotype [37]. These cells were shown to acquire CRPC-like features after culture in androgen-deprivation conditions, namely the expression of neuroendocrine (NE) and stem cell marker including neuron-specific enolase, neurotensin, CD133 and ALDH1A1, as well as androgen-independent proliferation [38–40]. The culture conditions employed induce a hormone-insensitive phenotype in LNCaP include the use of depleted or serum-free media, over extended periods of time, that can range from 3 months to 2 years [16,40].

In recent years, advanced in vitro systems for modeling prostate cancer have gained momentum. Growing PCa cells as spheroids or organoids, embedding them in 3D extracellular matrices, and using dynamic fluidic culture has enabled higher-fidelity recreation of in vivo biology under controlled experimental conditions [41,42]. In this study we employed an iteration of our PCa-microfluidic model [25], using LNCaP spheroids that display a robust epithelial phenotype, forming polarized structures with distinct regions, demarcated by differential expression of adhesion proteins, and enriched EGFR expression at the surface (Figure 2), prior to hormone-deprivation culture. After 30 days of culture under decreasing androgen levels, the spheroids exhibited a substantial shift in the expression profile of exosome-associated miRNAs. Exosomes serve as vehicles for cell-to-cell communication and are believed to play a critical role in PCa progression [43]. Shear stress generated under microfluidic culture conditions, combined with continuous fluid renewal at the cellular surface, has been reported to facilitate extracellular vesicle biogenesis and secretion [44,45]. These vesicles are released into the surrounding microenvironment and have been implicated in the transition of androgen-dependent PCa cells to androgen-independent states [46]. Malignant cells utilize exosomes to modulate the transcriptional

programs of neighboring cells, which is particularly relevant given the multifocal nature of PCa.

The hormone-deprivation culture conditions used in our study did not compromise spheroid viability. In fact, the resazurin-based assay (PrestoBlue) reported higher activity under dynamic perfusion, which is more likely linked to altered metabolic activity rather than increased proliferation, given that the dye is reduced by mitochondrial dehydrogenases. The stable PSA secretion observed over 30 days in microfluidic culture further supports the long-term robustness of the spheroids. The differences in PSA levels between static and dynamic culture may be due to flow-driven stimulation of PSA release; although recirculation does not alter the overall PSA content in the closed system, it likely enhances its diffusion out of the agar matrix in which the spheroids are embedded, improving measurable recovery.

Although circulating microRNAs are of considerable interest as potential diagnostic biomarkers, our analysis revealed that the expression of exosomal miRNAs in perfusate samples was highly variable, with substantial disparities observed between biological replicates (Figure A1). This inherent variability in secreted microRNAs is a well-recognized limitation that has hindered their reliable exploitation as clinical biomarkers [47,48]. In our analysis, significantly deregulated miRNAs in the perfusate did not overlap with intracellularly deregulated transcripts, although substantial miRNAs were present both intra- and extracellularly regardless of expression level. Interestingly, intracellularly expressed miRNAs are downregulated, while circulating transcripts are upregulated at Day 30 compared to Day 5, which may reflect accumulation of secreted exosomes in the perfusate over 30 days of closed culture. Exosomal sorting, which governs the selective packaging of extracellular vesicle cargo, may contribute to the discrepancies observed [49]. Tumor cells may selectively secrete oncogenic miRNAs as an adaptive mechanism to enhance their survival by modulating the behavior of neighboring cells. On the other hand, intracellular miRNA expression remained consistent across biological replicates. Downregulated miRNAs were linked to neuronal activity and differentiation, suggesting that the culture conditions promoted a shift in the LNCaP spheroids toward a NE-hybrid phenotype. The suppression of these transcripts is expected to positively regulate the expression of their target genes and associated cellular activity. Identified genes are associated with the PI3K-AKT-mTOR signaling pathway, cell cycle progression, epithelial-to-mesenchymal transition, and metastasis, all cellular processes central to PCa progression and the onset of CRPC [50,51]. Notably, the three most downregulated miRNAs, identified based on their number of interaction nodes, have previously been reported to exhibit tumor-suppressive activity in PCa. These miRNAs are also found to be downregulated in a clinical cohort of PCa samples (PRAD). *Mir-9-5p* has been shown to enhance the growth and metastatic potential of CD44⁺ prostate cancer stem cells [52], *miR-186* inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6 [53], while *miR-139-5p* suppresses proliferation by targeting Notch1 [54]. Our findings underscore the functional significance of coordinated miRNA activity in the transition to hormone-insensitive PCa. On the other hand, *mir-125b* was the sole significantly upregulated miRNA identified. This transcript is associated with genes regulating the activity of p53 (Figure A2), which deregulated activity is well documented in PCa progression [55,56]. These synergistic effects between reduced tumor-suppressive activity and enhanced genetic instability play an important role in progression to advanced PCa. The identified targets in our analysis (Table 2) include genes with experimentally validated miRNA–target interactions and established clinical associations (Figure 7). Neuropilin-1 (NRP1) has been implicated in PCa aggressiveness and progression through its roles in angiogenesis, growth factor signaling, and therapy resistance [57]. Phosphodiesterase 4D (PDE4D) regulates cAMP-dependent signaling pathways

that promote tumor cell proliferation and survival, and its dysregulation has been linked to advanced CRPC phenotypes [58]. Notably, PDE4D has been proposed as a potential therapeutic target in prostate cancer, given its druggability and contribution to oncogenic signaling [59]. The GATA zinc finger domain-containing 2B (GATAD2B) and Kinesin family member 3A (KIF3A) may contribute to epigenetic and signaling rewiring during disease progression [60,61]. The Zinc finger and BTB domain-containing 34 (ZBTB34) and RUN and FYVE domain-containing 3 (RUFY3) may contribute to regulatory roles downstream of miRNA control [62,63]. Despite their clinical association with PCa progression, the functional characterization of these genes is still limited.

Our microfluidic platform has demonstrated robust performance for modeling PCa progression and the transition to castration-resistant, despite being based on a single cell type. Contemporary studies using complex PCa models have incorporated endothelial cells or stromal cells to better mimic the tumor microenvironment [64,65]. Future work can extend dynamic culture beyond 30 days to determine whether the induced phenotypes are terminally differentiated or can be reverted after restoring androgens in culture. Additional cell types can also be included to capture immune interactions (e.g., macrophage population in the hydrogel). Long-term experiments will require active monitoring to prevent contamination and to track nutrient consumption, particularly glucose, to avoid metabolic starvation, an issue mitigated in the present study by replenishing culture media every five days during perfusate collection. Detection of circulating exosomal miRNAs could be improved by isolating vesicles from the perfusate, using enrichment methods (e.g., ultracentrifugation). Functional characterization of LNCaP spheroids post-perfusion is warranted to evaluate neuroendocrine trans-differentiation and epithelial–mesenchymal transition. Metabolic analyses will help define the energetic demands of dynamic culture and further validate the phenotypic shifts observed in our model. Overall, the robust long-term PCa spheroid culture shows that our model can support studies using patient-derived micro-tissues and organoid for personalized medicine applications, drug testing and biomarker discovery.




Figure 7. Progression-free survival (PFS) analysis of predicted targets of miRNAs downregulated in the experimental dataset with validate activity (Appendix C). Lower expression of Neuropilin-1 (NRP1) (A), Zinc Finger and BTB Domain Containing 34 (ZBTB34) (B), GATA zinc finger domain-containing protein 2B (GATAD2B) (C), RUN And FYVE Domain Containing 3 (RUFY3) (D) and Kinesin Family Member 3A (KIF3A) (E) was associated with longer PFS. On the other hand, a higher cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) (F) expression was associated with a longer PFS. The GEPIA3 tool was used to plot the PFS of selected genes against the TCGA-PRAD dataset.

5. Conclusions

The current study demonstrates that microfluidic culture of PCa spheroids under hormone-deprived conditions can induce pronounced phenotypic changes that recapitulate early steps of disease progression. This system provides a physiologically relevant and controlled environment in which the dynamic adaptation of cancer cells can be monitored over time, offering valuable insights into the transition from hormone-sensitive PCa to CRPC. LNCaP spheroids acquire a hybrid phenotype displaying NE features, where downregulated intracellular miRNAs target genes associated with PCa progression and poor clinical outcomes. Our model enables systematic characterization of microRNA signatures and their functional roles in CRPC development. Prospective studies will take into account the technical constraints associated with implementing miRNA-seq pipelines for microfluidic-derived samples, with the aim of generating robust biological replicates. In addition, future work will include paired miRNA and mRNA sequencing of the same samples under identical experimental conditions to enable direct matching of miRNAs with their targets. By combining spheroid culture with microRNA profiling, it is possible to identify regulatory pathways that drive aggressive phenotypes, test therapeutic interventions, and explore potential diagnostic markers.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/bioengineering13020204/s1>, Table S1: Diff_miR_Intracellular_Target_List; Table S2: GSEA_Results; Table S3: Readcount_TPM_Intracellular_Day30_Day5; Table S4: Readcount_TPM_Liquid_Day30_Day15_Day5.

Author Contributions: K.S. performed the experimental work involving cell and microfluidic culture, immunofluorescence characterization; viability testing and sample preparation, as well manuscript preparation. T.K. performed all the bioinformatic analysis including miRNA target identification, GSEA, plot preparation as well as manuscript preparation and editing; Z.Z. supported the ELISA and viability assays performed; M.B. supported the overall project administration and resource acquisition; C.R. supported the overall data analysis and impact on prostate cancer pathophysiology; P.C.P. oversaw the experimental work, data analysis as well as manuscript preparation and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the Deutsche Forschungsgemeinschaft (DFG), grant nr. 544003877.

Data Availability Statement: The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request. Tables containing the miRNA sequencing analysis, GSEA results, and miRNA target annotations are provided as the Supplementary Information.

Acknowledgments: During manuscript preparation, OpenAI ChatGPT-3.5 was employed exclusively to assist with the proofreading of selected sections of the text; no content was generated.

Conflicts of Interest: The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:

PCa	Prostate Cancer
BHP	Benign Prostatic Hyperplasia
HSPC	Hormone-Sensitive Prostate Cancer
CRPC	Castration-Resistant Prostate Cancer
miRNA	microRNA
FCS	Fetal Calf Serum
LDH	Lactate Dehydrogenase
ELISA	Enzyme-Linked Immunosorbent Assay

EGFR	Epidermal Growth Factor Receptor
ZO1	Zonula Occludens 1
GSEA	Gene Set Enrichment Analysis
NE	Neuroendocrine
ALDH1A1	Aldehyde Dehydrogenase 1 Family Member A1
CD	Cluster of Differentiation
CDK	Cyclin-Dependent Kinase
PI3K	Phosphoinositide 3-Kinase
AKT	Protein Kinase B
mTOR	Mechanistic Target of Rapamycin

Appendix A

Table A1. List of ELISA and assay kits used to evaluate PSA secretion and cell viability.

Assay	Type	Supplier	Reference
LDH release	Luminescent	Promega	J2380
Caspase 3/7	Luminescent	Promega	G8090
Presto Blue	Colorimetric	Invitrogen	A13261
PSA	ELISA	R&D Systems	DY1344

Table A2. List of antibodies used for immunofluorescent characterization.

Marker	Primary Antibody	Reactivity	Dilution	Secondary Antibody	Dilution	Reactivity
EGFR	Ab30 (acam)	Mouse α -human	1:100	A-31570 (Invitrogen)	1:200	Donkey α -mouse
Fibronectin	MAB19182 (R&D systems)	Mouse α -human	1:100		1:200	
Tubulin	T7451 (Merck)	Mouse α -human	1:500		1:200	
E-Cadherin	GTX125890 (GeneTex)	Rabbit α -human	1:100	A-21428 (Invitrogen)	1:200	Goat α -rabbit
ZO1	MA3-39100-A555 (Invitrogen)	Mouse α -human	1:100	-	1:200	-


Cells were counterstained with Hoechst 33342 (Merck; 14533) and Phalloidin-488 (Abcam; ab176753) at dilutions of 1:1000 and 1:2000, respectively, to highlight the nuclei in blue and the actin cytoskeleton in green. Primary antibody incubations were carried out overnight at 4 °C, followed by incubation with the corresponding secondary antibodies for 3 h at room temperature before imaging.

Appendix B

Appendix B.1



(A)



(B)

Figure A1. (A) Principal component analysis (PCA) plot illustrating the relationship between intracellular miRNA samples at Day 5 and Day 30, highlighting differences in expression profiles in the biological replicates; (B) Principal component analysis (PCA) plot illustrating the relationship between extracellular miRNA samples at Day 5 and Day 30, highlighting differences in expression profiles in the biological replicates. Samples from Day 15 were not included in our analysis.

Appendix B.2




Figure A2. Pathway analysis of predicted target genes depressed at Day 30 due to miR-125b up-regulation. **(A)** Reactome/biological pathway enrichment analysis. **(B)** Hallmark gene set enrichment (MSigDB) using the same set of de-repressed target genes, complementing the more detailed pathway-level information in Panel (A).

Appendix C

Table A3. Expression of corresponding mRNA target expression in the TCGA-PRAD dataset, focusing on experimentally validated targets of the three core miRNAs based on miRTarBase, and their association with PFS according to the GEPIA3 analysis. The pearson correlation coefficient (PCC) *p*-value is shown as adjust using the Benjamini–Hochberg method. Highlighted genes are accosiated with disease survival.

Target Gene	miRNA	Experiments	Support	PCC	<i>p</i> -Value	Survival Target	<i>p</i> -Value
ELAVL1	miR-9	Luciferase reporter assay // qRT-PCR // Western blot	Functional MTI	0.061359673	0.229808111	-	-
NRP1		Luciferase reporter assay // qRT-PCR // Western blot	Functional MTI	−0.01268271	0.791660929	Low survival associated with longer PFS	0.00017
MAP1B		Microarray	Functional MTI (Weak)	−0.031121285	0.543594083	-	-
CPEB4		Microarray // qRT-PCR	Functional MTI (Weak)	−0.136581211	0.005836257	-	-
KPNA1		CLASH	Functional MTI (Weak)	−0.345357646	7.82×10^{-14}	-	-
PHC3	miR-186	PAR-CLIP	Functional MTI (Weak)	−0.274273668	5.57×10^{-9}	-	-
SLC44A1		HITS-CLIP	Functional MTI (Weak)	−0.193723693	5.20×10^{-5}	-	-

Table A3. *Cont.*

Target Gene	miRNA	Experiments	Support	PCC	<i>p</i> -Value	Survival Target	<i>p</i> -Value
GATAD2B	miR-186	CLASH	Functional MTI (Weak)	−0.22442965	2.18×10^{-6}	Low survival associated with longer PFS	0.028
NAA15		PAR-CLIP	Functional MTI (Weak)	−0.147153636	0.002933897	-	-
PLS3		PAR-CLIP	Functional MTI (Weak)	−0.251028544	1.04×10^{-7}	-	-
RNF2		Sequencing	Functional MTI (Weak)	−0.267368134	1.25×10^{-8}	-	-
SLC30A7		PAR-CLIP	Functional MTI (Weak)	−0.205584217	1.56×10^{-5}	-	-
CNOT6L		CLASH	Functional MTI (Weak)	−0.231356294	1.10×10^{-6}	-	-
ZBTB34	miR-139	CLASH	Functional MTI (Weak)	0.016466576	0.739369481	Low survival associated with longer PFS	0.047
ATP7A		Luciferase reporter assay//qRT-PCR//Western blotting	Functional MTI	−0.029009017	0.571599106	-	-
PDE4D		Immunoblot//Luciferase reporter assay//qRT-PCR	Functional MTI	0.34800842	7.82×10^{-14}	Low survival associated with longer PFS	0.00048
PDE4DIP		HITS-CLIP	Functional MTI (Weak)	0.049181403	0.335827417	-	-
USP6NL		HITS-CLIP	Functional MTI (Weak)	−0.062535426	0.223889474	-	-
PHF6		CLIP-seq	Functional MTI (Weak)	−0.203325773	1.93×10^{-5}	-	-
TET2		CLIP-seq	Functional MTI (Weak)	−0.033452506	0.522340004	-	-
KBTBD8		CLIP-seq	Functional MTI (Weak)	0.032614054	0.530350001	-	-
USP47		CLIP-seq	Functional MTI (Weak)	−0.06874582	0.176104629	-	-
WDR26		CLIP-seq	Functional MTI (Weak)	−0.148473097	0.002701163	-	-
DNAJC5		CLIP-seq	Functional MTI (Weak)	−0.050387961	0.328171625	-	-
ABI2		CLIP-seq	Functional MTI (Weak)	0.031145584	0.543594083	-	-
RUFY3		CLIP-seq	Functional MTI (Weak)	0.071615684	0.165573286	Low survival associated with longer PFS	0.018
KIF3A		CLIP-seq	Functional MTI (Weak)	−0.059857285	0.241490613	Low survival associated with longer PFS	0.026
MGAT4A	miR-139	CLIP-seq	Functional MTI (Weak)	−0.059212116	0.245144284	No association	-
ZBTB34		PAR-CLIP	Functional MTI (Weak)	−0.173691858	0.00033449	Low survival associated with longer PFS	0.047
RFX7		CLIP-seq	Functional MTI (Weak)	0.01720995	0.739123662	-	-
NRP1		CLIP-seq	Functional MTI (Weak)	−0.065308153	0.201765673	Low survival associated with longer PFS	0.00017

Functional MTI: functional miRNA–target interaction. CLASH: Crosslinking, Ligation, and Sequencing of Hybrids. PAR-CLIP: Photoactivatable Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation. HITS-CLIP: High-Throughput Sequencing of RNA isolated by Cross-linking and Immunoprecipitation. CLIP-seq: Crosslinking and Immunoprecipitation sequencing.

References

1. Bergengren, O.; Pekala, K.R.; Matsoukas, K.; Fainberg, J.; Mungovan, S.F.; Bratt, O.; Bray, F.; Brawley, O.; Luckenbaugh, A.N.; Mucci, L.; et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors—A Systematic Review. *Eur. Urol.* **2023**, *84*, 191–206. [\[CrossRef\]](#)
2. Peter, M.R.; Bilenky, M.; Davies, A.; Isserlin, R.; Bader, G.D.; Fleshner, N.E.; Hirst, M.; Zoubeydi, A.; Bapat, B. Distinct DNA Methylation Patterns Associated with Treatment Resistance in Metastatic Castration Resistant Prostate Cancer. *Sci. Rep.* **2021**, *11*, 6630. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Wang, Z.; Zou, J.; Zhang, L.; Liu, H.; Jiang, B.; Liang, Y.; Zhang, Y. Comprehensive Analysis of the Progression Mechanisms of CRPC and Its Inhibitor Discovery Based on Machine Learning Algorithms. *Front. Genet.* **2023**, *14*, 1184704. [\[CrossRef\]](#) [\[PubMed\]](#)
4. He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a Big Role in Gene Regulation. *Nat. Rev. Genet.* **2004**, *5*, 522–531. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Mansoori, B.; Baradaran, B.; Nazari, A.; Gaballu, F.A.; Cho, W.C.-S.; Mansoori, B. MicroRNAs in the Cancer Cell-to-Cell Communication: An Insight into Biological Vehicles. *Biomed. Pharmacother.* **2022**, *153*, 113449. [\[CrossRef\]](#)
6. Jiang, Z.; Zhang, Y.; Chen, X.; Wu, P.; Chen, D. Inactivation of the Wnt/ β -Catenin Signaling Pathway Underlies Inhibitory Role of MicroRNA-129-5p in Epithelial–Mesenchymal Transition and Angiogenesis of Prostate Cancer by Targeting ZIC2. *Cancer Cell Int.* **2019**, *19*, 271. [\[CrossRef\]](#)
7. Woźniak, O.; Mierzejewski, B.; Brzoska, E. MicroRNA-126: A Key Regulator of Angiogenesis, Inflammation, and Tumorigenesis—Exploring Its Multifaceted Functions in Vascular Health and Cancer. *Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.* **2025**, *1871*, 167984. [\[CrossRef\]](#)
8. Juracek, J.; Madrzyk, M.; Stanik, M.; Slaby, O. Urinary MicroRNAs and Their Significance in Prostate Cancer Diagnosis: A 5-Year Update. *Cancers* **2022**, *14*, 3157. [\[CrossRef\]](#)
9. Orang, A.; Warnock, N.I.; Migault, M.; Dredge, B.K.; Bert, A.G.; Bracken, J.M.; Gregory, P.A.; Pillman, K.A.; Goodall, G.J.; Bracken, C.P. Chasing Non-Existent “MicroRNAs” in Cancer. *Oncogenesis* **2025**, *14*, 10. [\[CrossRef\]](#)
10. Ye, J.; Xu, M.; Tian, X.; Cai, S.; Zeng, S. Research Advances in the Detection of MiRNA. *J. Pharm. Anal.* **2019**, *9*, 217–226. [\[CrossRef\]](#)
11. Peng, Y.; Croce, C.M. The Role of MicroRNAs in Human Cancer. *Signal Transduct. Target. Ther.* **2016**, *1*, 15004. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Cui, M.; Wang, H.; Yao, X.; Zhang, D.; Xie, Y.; Cui, R.; Zhang, X. Circulating MicroRNAs in Cancer: Potential and Challenge. *Front. Genet.* **2019**, *10*, 626. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Vignard, V.; Labbé, M.; Marec, N.; André-Grégoire, G.; Jouand, N.; Fonteneau, J.-F.; Labarrière, N.; Fradin, D. MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma. *Cancer Immunol. Res.* **2020**, *8*, 255–267. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Alshahrani, S.H.; Ibrahim, Y.S.; Jalil, A.T.; Altoum, A.A.; Achmad, H.; Zabibah, R.S.; Gabr, G.A.; Ramírez-Coronel, A.A.; Alameri, A.A.; Qasim, Q.A.; et al. Metabolic Reprogramming by MiRNAs in the Tumor Microenvironment: Focused on Immunometabolism. *Front. Oncol.* **2022**, *12*, 1042196. [\[CrossRef\]](#)
15. Rönna, C.G.H.; Fussek, S.; Smit, F.P.; Aalders, T.W.; van Hooij, O.; Pinto, P.M.C.; Burchardt, M.; Schalken, J.A.; Verhaegh, G.W. Upregulation of MiR-3195, MiR-3687 and MiR-4417 Is Associated with Castration-Resistant Prostate Cancer. *World J. Urol.* **2021**, *39*, 3789–3797. [\[CrossRef\]](#)
16. Venz, S.; Junker, H.; Ultsch, E.; Hetke, F.; Krüger, E.; Burchardt, M.; Caetano-Pinto, P.; Roennau, C. Identification of the Regulatory Targets of MiR-3687 and MiR-4417 in Prostate Cancer Cells Using a Proteomics Approach. *Int. J. Mol. Sci.* **2022**, *23*, 10565. [\[CrossRef\]](#)
17. Li, C.; Zhou, T.; Chen, J.; Li, R.; Chen, H.; Luo, S.; Chen, D.; Cai, C.; Li, W. The Role of Exosomal MiRNAs in Cancer. *J. Transl. Med.* **2022**, *20*, 6. [\[CrossRef\]](#)
18. Nail, H.M.; Chiu, C.-C.; Leung, C.-H.; Ahmed, M.M.M.; Wang, H.-M.D. Exosomal MiRNA-Mediated Intercellular Communications and Immunomodulatory Effects in Tumor Microenvironments. *J. Biomed. Sci.* **2023**, *30*, 69. [\[CrossRef\]](#)
19. Agrawal, P.; Olgun, G.; Singh, A.; Gopalan, V.; Hannenhalli, S. Characterizing the Role of Exosomal MiRNAs in Metastasis. *bioRxiv* **2024**. [\[CrossRef\]](#)
20. Ghafouri-Fard, S.; Shirvani-Farsani, Z.; Branicki, W.; Taheri, M. MicroRNA Signature in Renal Cell Carcinoma. *Front. Oncol.* **2020**, *10*, 596359. [\[CrossRef\]](#)
21. Li, R.; Lu, C.; Li, X.; Chen, X.; Huang, G.; Wen, Z.; Li, H.; Tao, L.; Hu, Y.; Zhao, Z.; et al. A Four-MicroRNA Panel in Serum as a Potential Biomarker for Screening Renal Cell Carcinoma. *Front. Genet.* **2022**, *13*, 897827. [\[CrossRef\]](#) [\[PubMed\]](#)
22. Santos, D.A.R.; Eiras, M.; Gonzalez-Santos, M.; Santos, M.; Pereira, C.; Santos, L.L.; Dinis-Ribeiro, M.; Lima, L. A Preliminary Assessment of a Stool-Based MicroRNA Profile for Early Colorectal Cancer Screening. *Sci. Rep.* **2025**, *15*, 28597. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Jian, J.; Wang, X.; Zhang, J.; Zhou, C.; Hou, X.; Huang, Y.; Hou, J.; Lin, Y.; Wei, X. Molecular Landscape for Risk Prediction and Personalized Therapeutics of Castration-Resistant Prostate Cancer: At a Glance. *Front. Endocrinol.* **2024**, *15*, 1360430. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Singh, S.; Pathak, A.K.; Kural, S.; Kumar, L.; Bhardwaj, M.G.; Yadav, M.; Trivedi, S.; Das, P.; Gupta, M.; Jain, G. Integrating MiRNA Profiling and Machine Learning for Improved Prostate Cancer Diagnosis. *Sci. Rep.* **2025**, *15*, 30477. [\[CrossRef\]](#)
25. Padmyastuti, A.; Sarmiento, M.G.; Dib, M.; Ehrhardt, J.; Schoon, J.; Somova, M.; Burchardt, M.; Roennau, C.; Pinto, P.C. Microfluidic-Based Prostate Cancer Model for Investigating the Secretion of Prostate-Specific Antigen and MicroRNAs in Vitro. *Sci. Rep.* **2023**, *13*, 11623. [\[CrossRef\]](#)

26. Creighton, C.J.; Reid, J.G.; Gunaratne, P.H. Expression Profiling of MicroRNAs by Deep Sequencing. *Brief. Bioinform.* **2009**, *10*, 490–497. [\[CrossRef\]](#)
27. Wagner, G.P.; Kin, K.; Lynch, V.J. Measurement of mRNA Abundance Using RNA-Seq Data: RPKM Measure Is Inconsistent among Samples. *Theory Biosci.* **2012**, *131*, 281–285. [\[CrossRef\]](#)
28. Lange, T.; Stracke, S.; Rettig, R.; Lendeckel, U.; Kuhn, J.; Schlüter, R.; Rippe, V.; Endlich, K.; Endlich, N. Identification of MiR-16 as an Endogenous Reference Gene for the Normalization of Urinary Exosomal MiRNA Expression Data from CKD Patients. *PLoS ONE* **2017**, *12*, e0183435. [\[CrossRef\]](#)
29. Mu, W.; Zhang, W. Bioinformatic Resources of MicroRNA Sequences, Gene Targets, and Genetic Variation. *Front. Genet.* **2012**, *3*, 31. [\[CrossRef\]](#)
30. Betel, D.; Koppal, A.; Agius, P.; Sander, C.; Leslie, C. Comprehensive Modeling of MicroRNA Targets Predicts Functional Non-Conserved and Non-Canonical Sites. *Genome Biol.* **2010**, *11*, R90. [\[CrossRef\]](#)
31. Chen, Y.; Wang, X. MiRDB: An Online Database for Prediction of Functional MicroRNA Targets. *Nucleic Acids Res.* **2020**, *48*, D127–D131. [\[CrossRef\]](#)
32. Xiao, F.; Zuo, Z.; Cai, G.; Kang, S.; Gao, X.; Li, T. MiRecords: An Integrated Resource for MicroRNA-Target Interactions. *Nucleic Acids Res.* **2009**, *37*, D105–D110. [\[CrossRef\]](#)
33. Krek, A.; Grün, D.; Poy, M.N.; Wolf, R.; Rosenberg, L.; Epstein, E.J.; MacMenamin, P.; da Piedade, I.; Gunsalus, K.C.; Stoffel, M.; et al. Combinatorial MicroRNA Target Predictions. *Nat. Genet.* **2005**, *37*, 495–500. [\[CrossRef\]](#)
34. Kertesz, M.; Iovino, N.; Unnerstall, U.; Gaul, U.; Segal, E. The Role of Site Accessibility in MicroRNA Target Recognition. *Nat. Genet.* **2007**, *39*, 1278–1284. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Agarwal, V.; Bell, G.W.; Nam, J.-W.; Bartel, D.P. Predicting Effective MicroRNA Target Sites in Mammalian MRNAs. *elife* **2015**, *4*, e05005. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Sampson, N.; Neuwirt, H.; Pühr, M.; Klocker, H.; Eder, I.E. In Vitro Model Systems to Study Androgen Receptor Signaling in Prostate Cancer. *Endocr. Relat. Cancer* **2013**, *20*, R49–R64. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Abate-Shen, C.; Nunes de Almeida, F. Establishment of the LNCaP Cell Line-The Dawn of an Era for Prostate Cancer Research. *Cancer Res.* **2022**, *82*, 1689–1691. [\[CrossRef\]](#)
38. Yuan, T.-C.; Veeramani, S.; Lin, F.-F.; Kondrikou, D.; Zelivianski, S.; Igawa, T.; Karan, D.; Batra, S.K.; Lin, M.-F. Androgen Deprivation Induces Human Prostate Epithelial Neuroendocrine Differentiation of Androgen-Sensitive LNCaP Cells. *Endocr. Relat. Cancer* **2006**, *13*, 151–167. [\[CrossRef\]](#)
39. Sánchez, B.G.; Bort, A.; Vara-Ciruelos, D.; Díaz-Laviada, I. Androgen Deprivation Induces Reprogramming of Prostate Cancer Cells to Stem-Like Cells. *Cells* **2020**, *9*, 1441. [\[CrossRef\]](#)
40. Kokontis, J.M.; Hay, N.; Liao, S. Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for P27Kip1 in Androgen-Induced Cell Cycle Arrest. *Mol. Endocrinol.* **1998**, *12*, 941–953. [\[CrossRef\]](#)
41. Sánchez-de-Diego, C.; Yada, R.C.; Sethakorn, N.; Geiger, P.G.; Ding, A.B.; Heninger, E.; Ahmed, F.; Virumbrales-Muñoz, M.; Lupsa, N.; Bartels, E.; et al. Engineering the Bone Metastatic Prostate Cancer Niche through a Microphysiological System to Report Patient-Specific Treatment Response. *Commun. Biol.* **2025**, *8*, 961. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Gao, D.; Vela, I.; Sboner, A.; Iaquinta, P.J.; Karthaus, W.R.; Gopalan, A.; Dowling, C.; Wanjala, J.N.; Undvall, E.A.; Arora, V.K.; et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. *Cell* **2014**, *159*, 176–187. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Lorenc, T.; Klimczyk, K.; Michalczywska, I.; Słomka, M.; Kubiak-Tomaszewska, G.; Olejars, W. Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy. *Int. J. Mol. Sci.* **2020**, *21*, 2118. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Thompson, W.; Papoutsakis, E.T. The Role of Biomechanical Stress in Extracellular Vesicle Formation, Composition and Activity. *Biotechnol. Adv.* **2023**, *66*, 108158. [\[CrossRef\]](#)
45. Park, H.; Seo, Y.-K.; Arai, Y.; Lee, S.-H. Physicochemical Modulation Strategies for Mass Production of Extracellular Vesicle. *Tissue Eng. Regen. Med.* **2025**, *22*, 569–591. [\[CrossRef\]](#)
46. Zhang, Y.; Chen, B.; Xu, N.; Xu, P.; Lin, W.; Liu, C.; Huang, P. Exosomes Promote the Transition of Androgen-Dependent Prostate Cancer Cells into Androgen-Independent Manner Through Up-Regulating the Heme Oxygenase-1. *Int. J. Nanomed.* **2021**, *16*, 315–327. [\[CrossRef\]](#)
47. Srivastava, A.; Suy, S.; Collins, S.P.; Kumar, D. Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. *Mol. Cell. Pharmacol.* **2011**, *3*, 115–124.
48. Keller, A.; Rounge, T.; Backes, C.; Ludwig, N.; Gislefoss, R.; Leidinger, P.; Langseth, H.; Meese, E. Sources to Variability in Circulating Human MiRNA Signatures. *RNA Biol.* **2017**, *14*, 1791–1798. [\[CrossRef\]](#)
49. Wei, H.; Chen, Q.; Lin, L.; Sha, C.; Li, T.; Liu, Y.; Yin, X.; Xu, Y.; Chen, L.; Gao, W.; et al. Regulation of Exosome Production and Cargo Sorting. *Int. J. Biol. Sci.* **2021**, *17*, 163–177. [\[CrossRef\]](#)
50. Edlind, M.; Hsieh, A. PI3K-AKT-MTOR Signaling in Prostate Cancer Progression and Androgen Deprivation Therapy Resistance. *Asian J. Androl.* **2014**, *16*, 378. [\[CrossRef\]](#)

51. Dicken, H.; Hensley, P.J.; Kyprianou, N. Prostate Tumor Neuroendocrine Differentiation via EMT: The Road Less Traveled. *Asian J. Urol.* **2019**, *6*, 82–90. [[CrossRef](#)] [[PubMed](#)]
52. Wang, X.; Cai, J.; Zhao, L.; Zhang, D.; Xu, G.; Hu, J.; Zhang, T.; Jin, M. NUMB Suppression by MiR-9-5P Enhances CD44+ Prostate Cancer Stem Cell Growth and Metastasis. *Sci. Rep.* **2021**, *11*, 11210. [[CrossRef](#)] [[PubMed](#)]
53. Lu, S.; Wang, M.-S.; Chen, P.-J.; Ren, Q.; Bai, P. MiRNA-186 Inhibits Prostate Cancer Cell Proliferation and Tumor Growth by Targeting YY1 and CDK6. *Exp. Ther. Med.* **2017**, *13*, 3309–3314. [[CrossRef](#)] [[PubMed](#)]
54. Sun, Q.; Weng, D.; Li, K.; Li, S.; Bai, X.; Fang, C.; Luo, D.; Wu, P.; Chen, G.; Wei, J. MicroRNA-139-5P Inhibits Human Prostate Cancer Cell Proliferation by Targeting Notch1. *Oncol. Lett.* **2018**, *16*, 793–800. [[CrossRef](#)]
55. Yanushko, D.; German Falcon, B.; El Bizri, R.; Pervizou, D.; Dolgos, R.; Keime, C.; Ye, T.; Thibault-Carpentier, C.; Le Magnen, C.; Henri, S.; et al. P53-Loss Induced Prostatic Epithelial Cell Plasticity and Invasion Is Driven by a Crosstalk with the Tumor Microenvironment. *Cell Death Dis.* **2025**, *16*, 46. [[CrossRef](#)]
56. Burchardt, M.; Burchardt, T.; Shabsigh, A.; Ghafar, M.; Chen, M.; Anastasiadis, A.; de la Taille, A.; Kiss, A.; Buttyan, R. Reduction of Wild Type P53 Function Confers a Hormone Resistant Phenotype on LNCaP Prostate Cancer Cells*. *Prostate* **2001**, *48*, 225–230. [[CrossRef](#)]
57. Zhang, P.; Chen, L.; Zhou, F.; He, Z.; Wang, G.; Luo, Y. NRP1 Promotes Prostate Cancer Progression via Modulating EGFR-Dependent AKT Pathway Activation. *Cell Death Dis.* **2023**, *14*, 159. [[CrossRef](#)]
58. van Strijp, D.; de Witz, C.; Heitkötter, B.; Huss, S.; Bögemann, M.; Baillie, G.S.; Houslay, M.D.; Bangma, C.; Semjonow, A.; Hoffmann, R. The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour's TMPRSS2-ERG Fusion Status. *Prostate Cancer* **2019**, *2019*, 8107807. [[CrossRef](#)]
59. Powers, G.L.; Hammer, K.D.P.; Domenech, M.; Frantskevich, K.; Malinowski, R.L.; Bushman, W.; Beebe, D.J.; Marker, P.C. Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential. *Mol. Cancer Res.* **2015**, *13*, 149–160. [[CrossRef](#)]
60. Jin, Z.; Wang, H.; Tang, R.; Pan, B.; Lee, H.-J.; Liu, S.; Wang, L.; Qin, J.; Xu, M. GATA2 Promotes Castration-Resistant Prostate Cancer Development by Suppressing IFN- β Axis-Mediated Antitumor Immunity. *Oncogene* **2024**, *43*, 2595–2610. [[CrossRef](#)]
61. Liu, Z.; Rebowe, R.E.; Wang, Z.; Li, Y.; Wang, Z.; DePaolo, J.S.; Guo, J.; Qian, C.; Liu, W. KIF3a Promotes Proliferation and Invasion via Wnt Signaling in Advanced Prostate Cancer. *Mol. Cancer Res.* **2014**, *12*, 491–503. [[CrossRef](#)]
62. Ding, G.; Lu, W.; Zhang, Q.; Li, K.; Zhou, H.; Wang, F.; Zhao, C.; Fan, C.; Wang, J. ZBTB38 Suppresses Prostate Cancer Cell Proliferation and Migration via Directly Promoting DKK1 Expression. *Cell Death Dis.* **2021**, *12*, 998. [[CrossRef](#)] [[PubMed](#)]
63. Keren-Kaplan, T.; Sarić, A.; Ghosh, S.; Williamson, C.D.; Jia, R.; Li, Y.; Bonifacino, J.S. RUFY3 and RUFY4 Are ARL8 Effectors That Promote Coupling of Endolysosomes to Dynein-Dynactin. *Nat. Commun.* **2022**, *13*, 1506. [[CrossRef](#)] [[PubMed](#)]
64. Kerr, S.C.; Morgan, M.M.; Gillette, A.A.; Livingston, M.K.; Lugo-Cintrón, K.M.; Favreau, P.F.; Florek, L.; Johnson, B.P.; Lang, J.M.; Skala, M.C.; et al. A Bioengineered Organotypic Prostate Model for the Study of Tumor Microenvironment-Induced Immune Cell Activation. *Integr. Biol.* **2020**, *12*, 250–262. [[CrossRef](#)] [[PubMed](#)]
65. Monteiro, M.V.; Moreira-Silva, F.; Lagarto, M.; Ferreira, L.P.; Ramalhinho, C.; Duarte, I.F.; Jerónimo, C.; Gaspar, V.M.; Mano, J.F. Bioengineered Tumor-Stroma Prostate Cancer In Vitro Models for Screening Therapeutics. *Biotechnol. Bioeng.* **2025**, *122*, 1541–1553. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.